Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapeutics symbols : MRTX save search
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Published: 2023-11-10 (Crawled : 12:30) - prnewswire.com
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: 0.4%
H: 0.18%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
krasg12 lung chmp positive cancer cell treatment therapeutics
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Published: 2023-11-06 (Crawled : 15:00) - biospace.com/
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: 0.61%
H: 0.77%
C: -0.66%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.75%
H: 0.59%
C: 0.27%
therapeutics financial results
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: -0.9%
H: 1.08%
C: 0.61%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.2%
H: 0.43%
C: -0.38%
KURA | News | $18.73 2.97% 2.93% 800K
|
Health Technology
|
| O: 0.13%
H: 6.0%
C: 5.25%
ko-2806 collaboration therapeutics agreement
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Published: 2023-09-05 (Crawled : 20:00) - prnewswire.com
MS | News 0 d | $93.76 1.81% -0.24% 5M
|
Finance
|
| O: -1.87%
H: 0.0%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.36%
H: 0.86%
C: -1.17%
nasdaq grant therapeutics
Mirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
Published: 2023-08-29 (Crawled : 20:00) - prnewswire.com
MS | News 0 d | $93.76 1.81% -0.24% 5M
|
Finance
|
| O: 1.44%
H: 0.0%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.69%
H: 1.04%
C: 1.01%
conference global therapeutics
Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Published: 2023-08-11 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
| Email alert
Add to watchlist
offering therapeutics
Mirati Therapeutics Announces Pricing of Upsized Public Offering - August 09, 2023
Published: 2023-08-09 (Crawled : 11:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 23.42%
H: 8.46%
C: 6.87%
offering therapeutics
Mirati Therapeutics Announces Pricing of Upsized Public Offering
Published: 2023-08-09 (Crawled : 05:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 23.42%
H: 8.46%
C: 6.87%
offering therapeutics
Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023
Published: 2023-07-25 (Crawled : 21:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: -2.19%
therapeutics report financial results
Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation
Published: 2023-07-21 (Crawled : 12:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -14.97%
H: 11.97%
C: 8.9%
lung review update cancer cell treatment therapeutics
Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director
Published: 2023-06-23 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
| Email alert
Add to watchlist
therapeutics
Mirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023
Published: 2023-06-01 (Crawled : 22:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.89%
H: 1.36%
C: 0.49%
conference global therapeutics
Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®
Published: 2023-05-24 (Crawled : 20:00) - prnewswire.com
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: -0.81%
H: 0.32%
C: -0.59%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -6.18%
H: 0.0%
C: -6.64%
opdivo update sapphire therapeutics study
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Published: 2023-05-05 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
| Email alert
Add to watchlist
nasdaq grant therapeutics
Mirati Therapeutics to Participate at the Bank of America Securities 2023 Health Care Conference
Published: 2023-04-27 (Crawled : 22:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 1.44%
H: 0.66%
C: -0.21%
america conference health care therapeutics
Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023
Published: 2023-04-25 (Crawled : 21:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.67%
H: 1.16%
C: 0.3%
therapeutics report financial results
Mirati Therapeutics to Participate at the Barclays Global Healthcare Conference
Published: 2023-03-06 (Crawled : 22:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.05%
H: 2.48%
C: 0.41%
global conference therapeutics
Mirati Therapeutics to Participate at the 43rd Annual Cowen Health Care Conference
Published: 2023-02-21 (Crawled : 22:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 1.1%
H: 1.12%
C: 0.39%
care conference health therapeutics
Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2022 and Recent Corporate Updates on February 28, 2023
Published: 2023-02-14 (Crawled : 22:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -1.11%
H: 2.41%
C: 1.61%
report year therapeutics financial
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Published: 2023-02-03 (Crawled : 22:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
| Email alert
Add to watchlist
nasdaq grant therapeutics
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
ZAPP | $4.44 50.2% 33.12% 370K
|
n/a
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.045 35.33% 26.23% 870K
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
Your saved searches
Save your searches and get alerts when important news are released.